ÖÜ¿¯ 1997Äê1Ô´´¿¯£¨×ܵÚ319ÆÚ£© µÚ12¾í µÚ11ÆÚ 2008Äê3ÔÂ11ÈÕ³ö°æ


´Ì¼¤ÐÔGµ°°×ÔÚ²¡ÀíÐÔñ£ºÛ×éÖ¯Öеıí´ï*¡î ÿ

ÁÎÁ¢Ð£¬Íõ¾¹Åô


¿ÎÌâ±³¾°£ºGµ°°×ÐźÅתµ¼Í¾¾¶ÊÇÖØÒªµÄÊÜÌå½éµ¼¿çĤÐźÅתµ¼Í¾¾¶¡£Gµ°°×żÁªÊÜÌåÒѾ­±»Ö¤ÊµÓ벡ÀíÐÔñ£ºÛµÄÐγÉÓйأ¬¶ø¶ÔÓÚ´«µ¼¹ý³ÌÖйؼüÐÔÖм䵰°×--Gµ°°×µÄÑо¿È´ÉÙ¼û±¨µÀ¡£Òò´Ë̽Ìִ̼¤ÐÔGµ°°×ÊÇ·ñ²ÎÓëÁ˲¡ÀíÐÔñ£ºÛºÍÕý³£Æ¤·ôµÄϸ°û¿çĤÐźÅתµ¼£¬ÔÚÄÄЩϸ°ûÖÐÆð×÷ÓÃÒÔ¼°´Ì¼¤ÐÔGµ°°×ÔÚ²¡ÀíÐÔñ£ºÛÐγÉÖеÄ×÷Ó㬿ÉΪ·ÀÖβ¡ÀíÐÔñ£ºÛÌṩеÄÀíÂÛÒÀ¾Ý¡£

ͬÐÐÆÀ¼Û£º²¡ÀíÐÔñ£ºÛÐγɻúÖÆÒ»Ö±ÊÇҽѧÑо¿µÄÈȵ㣬Gµ°°×ÊÇϸ°ûÐźÅתµ¼µÄÖØÒªÍ¾¾¶¡£ÊµÑé¼ì²â´Ì¼¤ÐÔGµ°°×ÔÚ²¡ÀíÐÔñ£ºÛ×éÖ¯Öбí´ï£¬Ì½ÌÖGµ°°×ÐźÅתµ¼Í¾¾¶¶Ô²¡ÀíÐÔñ£ºÛÐγɵÄÓ°Ï죬ѡÌâÓÐÐÂÒ⣬¿ÆÑÐÉè¼Æ½ÏºÏÀí£¬·½·¨¿ÉÐУ¬½á¹û¿É¿¿£¬Îª²¡ÀíÐÔñ£ºÛÐγɵķÖ×ÓÉúÎïѧ»úÖÆÑо¿ÌṩÁËеÄ˼·¡£

Ïà¹ØÁ´½Ó£ºÏ¸°ûÐźŴ«µ¼Í¾¾¶°üÀ¨ºÜ¶à£¬Ö÷ÒªÓÐϸ°û¼ä¡¢Ï¸°ûÄÚ¡¢Ï¸°ûÓëÖÜΧÎïÖÊ¡¢Ï¸°û¿çĤÐźŴ«µ¼µÈ£¬¶Ôϸ°û¿çĤÐźŴ«µ¼µÄÑо¿ÒѾ­³ÉΪеÄÈȵ㡣Gµ°°×ÊÇÖØÒªµÄ¿çĤÐźÅתµ¼µ°°×£¬²ÎÓë¹ã·ºµÄϸ°ûÉúÎïѧ»î¶¯¡£¹úÄÚ¶Ô¼±ÐÔ·ÎËðÉ˺óÍõķζ¯Âö¡¢Ðļ¡¡¢ÄÔµÈ×éÖ¯¡¢Ïø´­ëàÊó·Î×éÖ¯µÈGµ°°×µÄ±ä»¯½øÐÐÁËϵͳµÄÑо¿£¬Ö¤ÊµGµ°°×ÓëÐí¶à¼²²¡Óйء£¶ø¶Ô²¡ÀíÐÔñ£ºÛÖÐGµ°°×µÄ×÷ÓÃÉв»Çå³þ¡£

Äϲý´óѧµÚÒ»¸½ÊôÒ½ÔºÉÕÉËÖÐÐÄ£¬½­Î÷Ê¡ÄϲýÊÐ
330006

ÁÎÁ¢Ð¡ÄУ¬1966ÄêÉú£¬½­Î÷Ê¡¸ß°²ÏØÈË£¬ºº×壬2003Äê½­Î÷ҽѧԺ±ÏÒµ£¬²©Ê¿£¬Ö÷ÈÎҽʦ£¬Ö÷Òª´ÓÊÂÉÕÉË´´ÃæÐÞ¸´Ñо¿¡£
llx200532@sina.com

¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð×ÊÖúÏîÄ¿£¨30660234£©*

ÕªÒª
Ä¿µÄ:±È½ÏÔöÉúÐÔñ£ºÛ×éÖ¯ºÍÕý³£Æ¤·ô×éÖ¯´Ì¼¤ÐÔGµ°°×µÄ±í´ï²îÒ죬ÒÔÃ÷È·´Ì¼¤ÐÔGµ°°×²¡ÀíÐÔñ£ºÛÐγÉÖеÄ×÷ÓûúÖÆ¼°ÆäÔÚÄÄЩϸ°ûÖз¢»Ó×÷Óá£
·½·¨£ºÊµÑéÓÚ2005-09/2006-12ÔÚÄϲý´óѧµÚÒ»¸½ÊôÒ½ÔºÉÕÉËÑо¿ËùʵÑéÊÒÍê³É¡£ È¡10Àý18~38Ëêñ£ºÛÕûÐÎÊÖÊõ»¼ÕßÊõÖÐÊ£ÓàµÄÈ«ºñÕý³£Æ¤·ôºÍÇгýµÄ²¡ÀíÐÔñ£ºÛ×éÖ¯£¬²ÉÓÃPR-PCR·¨¼ì²â´Ì¼¤ÐÔGµ°°×µÄ»ùÒò±í´ï£¬ÃâÒß×éÖ¯»¯Ñ§·¨¼ì²âGµ°°×µÄ±í´ï£¬±È½Ï²¡ÀíÐÔñ£ºÛ×éÖ¯ÓëÕý³£Æ¤·ô×éÖ¯¼äµÄ²îÒì¡£
½á¹û£º¢ÙPR-PCR·¨¼ì²â·¢ÏÖÁ½ÖÖ×éÖ¯¾ùÓд̼¤ÐÔGµ°°×»ùÒò±í´ï£¬ÀûÓÃÄý½ºÍ¼Ïñ´¦Àíϵͳ·ÖÎö£¬²¡ÀíÐÔñ£ºÛºÍÄÚ²ÎÕÕ±ÈÖµ¸ßÓÚÕý³£Æ¤·ôºÍÄÚ²ÎÕÕ£¨P < 0.05£©¡£¢ÚÃâÒß×éÖ¯»¯Ñ§¼ì²âºó·¢ÏÖÁ½ÖÖ×éÖ¯¾ùÓд̼¤ÐÔGµ°°×µÄ±í´ï£¬¾ù·Ö²¼ÔÚ±íÆ¤µÄ»ùµ×ϸ°ûÄÚ¡¢ÕæÆ¤µÄ³ÉÏËάϸ°ûÄÚºÍëϸѪ¹ÜµÄÄÚÆ¤Ï¸°ûÄÚ¡£ÔÚϸ°ûÄÚ±í´ïµÄ²¿Î»·ûºÏGµ°°×µÄ±¾ÉíÐÔÖÊ£¨°û½¬²à£©£¬Á½ÖÖ×éÖ¯µÄ±í´ï·Ö²¼Ã»ÓÐÃ÷ÏÔ²îÒì¡£¢Û´óÌå¹Û²ì²¡ÀíÐÔñ£ºÛ×éÖ¯ºÍÕý³£Æ¤·ôµÄ»ùµ×ϸ°û´Ì¼¤ÐÔGµ°°×±í´ï¾ùΪÑôÐÔ£¬µ«ÎÞÃ÷ÏÔ²îÒì£»ÕæÆ¤µÄ³ÉÏËάϸ°ûÄÚºÍëϸѪ¹ÜÄÚÆ¤Ï¸°ûÄÚ²¡ÀíÐÔñ£ºÛµÄ±í´ïÇ¿ÓÚÕý³£Æ¤·ô¡£
½áÂÛ£º´Ì¼¤ÐÔGµ°°×¿ÉÄܲÎÓ벡ÀíÐÔñ£ºÛÖгÉÏËάϸ°ûºÍëϸѪ¹ÜÄÚÆ¤Ï¸°ûµÄÔöÖ³µ÷¿Ø¡£
¹Ø¼ü´Ê£º´Ì¼¤ÐÔGµ°°×£»²¡ÀíÐÔñ£ºÛ£»Æ¤·ô£»×éÖ¯¹¹½¨

ÁÎÁ¢Ð£¬Íõ¾¹Åô.´Ì¼¤ÐÔGµ°°×ÔÚ²¡ÀíÐÔñ£ºÛ×éÖ¯Öеıí´ï[J].Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´£¬2008£¬12(11):2051-2055 [www.zglckf.com/zglckf/ejournal/upfiles/08-11/11k-2051(ps).pdf]

ÖÐͼ·ÖÀàºÅ:R619.6
ÎÄÏ×±êʶÂë:A
ÎÄÕ±àºÅ:1673-8225
(2008)11-02051-05

ÊÕ¸åÈÕÆÚ£º2007-08-17 ÐÞ»ØÈÕÆÚ£º2007-10-13 £¨07-50-8-4468/N¡¤A£©

Stimulatory G protein expression in pathological scar

Abstract

AIM:To compare the expression difference in stimulatory G protein between hyperplastic scar and normal skin, so as to explore the formation mechanism of pathological scar.
METHODS: The experiment was conducted in the laboratory of Burn Center, First Affiliated Hospital of Nanchang University from September 2005 to December 2006. All-thickness normal skin and pathological scar were from patients aged 18£­38 years old who underwent scar plastic operation. The expression of stimulatory G protein mRNA in sample was detected using PR-PCR method, and G protein expression was detected using immunohistochemical method. The expressions in pathological scar and normal skin were compared.
RESULTS: ¢ÙStimulatory G protein mRNA expression was found in both tissues by PR-PCR. But gel image processing system analysis showed that pathological scar Gs ¦Á£¯¦Â-action was significantly higher than normal skin Gs ¦Á£¯¦Â-action (P < 0.05). ¢ÚImmunohistochemical detection suggested that the expression of stimulatory G protein was found in both pathological scar and normal skin, distributing in epidermal basal cell, hypodermal fibroblast and blood capillary endothelial cell. The distribution of expression in the two tissues had no difference. ¢ÛIn gross observation, positive expression in epidermal basal cell of pathological scar and normal skin had no obvious difference. The expression in hypodermal fibroblast and blood capillary endothelial cell of pathological scar was stronger than that in normal skin.
CONCLUSION: Stimulatory G protein may play a role in the proliferation and regulation of fibroblast and blood capillary endothelial cell in pathological scar.

Liao LX, Wang JP.Stimulatory G protein expression in pathological scar.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2008;12(11):2051-2055(China) [www.zglckf.com/zglckf/ejournal/upfiles/08-11/11k-2051(ps).pdf]


0 ÒýÑÔ

²¡ÀíÐÔñ£ºÛÐγɵķÖ×ÓÉúÎïѧ»úÖÆµÄÑо¿¶à¼¯ÖÐÔÚѪ¹ÜÐγɡ¢Ï¸°û³É·Ö¡¢Ï¸°ûÒò×Ó¡¢½ºÔ­´úлµÈ·½Ãæ[1]£¬ËäÈ»Ñо¿·½ÏòºÜ¶à£¬µ«ÊÇ×îÖÕÒªÃæÁÙÒ»¸öÎÊÌ⣬ÕâЩÒòËØÊÇͨ¹ýºÎÖÖ;¾¶Ó°Ï쵽ϸ°ûÄÚµÄÎïÖʱ仯µÄÄØ£¿½üÄêÀ´ºÜ¶àÑо¿»ú¹¹¿ªÊ¼¶Ô²¡ÀíÐÔñ£ºÛµÄϸ°ûÐźŴ«µ¼»úÖÆ½øÐÐÑо¿£¬²¢ÇÒÈ¡µÃÁËÒ»Ð©ÖØÒªµÄ½øÕ¹¡£Ä¿Ç°·¢ÏֵIJ¡ÀíÐÔñ£ºÛµÄϸ°û¿çĤ;¾¶ÐźÅתµ¼Í¾¾¶ºÜ¶à£¬Èçµ°°×ÀÒ°±Ëἤø;¾¶µÈµÈ¡£Gµ°°×ÐźÅתµ¼Í¾¾¶ÊÇĿǰÒÑÖªµÄ5ÌõÊÜÌå½éµ¼¿çĤÐźÅתµ¼Í¾¾¶ÖеÄÒ»Ìõ£¬´óÁ¿µÄGµ°°×żÁªÊÜÌåÒѾ­±»Ö¤ÊµÓ벡ÀíÐÔñ£ºÛµÄÐγÉÓйأ¬Èç°×ϸ°û½éËØ1ÊÜÌåµÈ[2-4]¡£ÄÇô¶Ô²¡ÀíÐÔñ£ºÛGµ°°×µÄÑо¿½«½øÒ»²½½Ò¿ªºÍ·á¸»²¡ÀíÐÔñ£ºÛϸ°ûÐźÅתµ¼µÄ»úÖÆ¡£

1 ²ÄÁϺͷ½·¨

Éè¼Æ£ºµ¥Ò»Ñù±¾¡¢×ÔÉí¶ÔÕÕÉè¼Æ¡£
µ¥Î»£ºÄϲý´óѧµÚÒ»¸½ÊôÒ½Ôº¡£
²ÄÁÏ£ºÊµÑéÓÚ2005-09/2006-12ÔÚÄϲý´óѧµÚÒ»¸½ÊôÒ½ÔºÉÕÉËÑо¿ËùʵÑéÊÒÍê³É¡£
±ê±¾»ñÈ¡£ºÊÖÊõÇÐÈ¡10Àý18~38ËêµÄÄϲý´óѧµÚÒ»¸½ÊôÒ½ÔºÉÕÉËÖÐÐÄñ£ºÛÕûÐÎÊÖÊõ»¼ÕßÊõÖÐÊ£ÓàµÄÈ«ºñÕý³£Æ¤·ôºÍÇгýµÄ²¡ÀíÐÔñ£ºÛ×éÖ¯£¬Ã¿Àý»¼ÕßÈ¡²¡ÀíÐÔñ£ºÛºÍÕý³£Æ¤·ô¸÷2¿é¡£¾ùͨ¹ý»¼Õß¼ÒÊôºÍ±¾ÈËͬÒâ¡£²¡³ÌÔÚÉÕÉË´´ÃæÓúºÏºó6~9¸öÔ£¬ÔÚ´ËÆÚ¼äûÓнÓÊÜÕë¶Ôñ£ºÛµÄ¸÷ÖÖÖÎÁÆ¡£ÒÔÉϱ걾¾ù¾­¹ý²¡ÀíËÕľ¾«-ÒÁºìȾɫ֤ʵ¡£½«ÊÖÊõȡϵÄ×éÖ¯±ê±¾¼ôСºó·ÖװѸËÙ×°ÈëÒºµª¹ÞÖб¸Óá£
ÊÔ¼Á£º×ÜRNAÌáÈ¡ºÐ100 mL (TRNzol) LOT#F4104(TIANGEN¹«Ë¾)£»Òì±û´¼100 mL£¬ÎÞË®ÒÒ´¼100 mL£¬ÂÈ·Â500 mL (ÒÔÉÏ3ÖÖ¾ùΪÉϺ£»¯Ñ§ÊÔ¼Á¹«Ë¾)£»ÎÞRNAø(Rnase)Ë®25 mL LOT#21389901(ÃÀ¹úPromega¹«Ë¾)£»DEPCË®5G DB0154 LOT 0104S04 (½ÝÈðÉúÎ﹤³Ì(ÉϺ£)ÓÐÏÞ¹«Ë¾)£»·´×ªÂ¼ÊÔ¼ÁºÐ100ÈË´Î CAT.#A3802 (ÃÀ¹úPromega¹«Ë¾)£»PCR·´Ó¦ÊÔ¼ÁºÐ100ÈË´ÎCAT.#A3802 (ÃÀ¹úPromega¹«Ë¾)£»ÒýÎïºÍ¦Â-action(ÄÚ²ÎÕÕ)¾ùÓɱ±¾©¾ùҢΰҵÉúÎï¼¼Êõ¹«Ë¾ºÏ³É£»ÇíÖ¬ÌǵçÓ¾10 g (ÃÀ¹úPromega¹«Ë¾)£»Maker Dill2000 (TIANGEN¹«Ë¾)£»äåÒÒ¶§¡¢äå·ÒÀ¶ (±±¾©Ò½Ñ§ÉúÎ﹫˾)£»´Ì¼¤ÐÔGµ°°×Íÿ¹È˶à¿Ë¡¿¹Ìå(Ò»¿¹) G¦Ás (K-20)£ºSC-823(ÃÀ¹úSANTA CRUZ¹«Ë¾)£»¶þ¿¹(¿¹ÍÃ)(ÉϺ£ÉúÎï¼¼Êõ¹«Ë¾)£»SPÃâÒß×黯ÊÔ¼Á (¸£½¨ÂõÐÂÉúÎ﹫˾)¡¢DABÏÔÉ«¼Á (¸£½¨ÂõÐÂÉúÎ﹫˾)¡£
Ö÷ÒªÒÇÆ÷£º-80 ¡æ ³¬µÍαùÏ䣬-86 ¡æ UTL-FREEZER(ÃÀ¹úTHERMO FORMA¹«Ë¾)£»³¬¾»¹¤×÷̨£ºHEAL-FORCE (ÉϺ£Á¦»ª¿Æ¼¼¹«Ë¾)£»¸ßËÙµÍÎÂÀëÐÄ»ú(Beckman¹«Ë¾)£»Ì¨Ê½¸ßËÙÀëÐÄ»ú TGL-16G (ÉϺ£Ò½ÓÃÒÇÆ÷³§)£»Î¢Á¿Ì¨Ê½¼ÓÈÈÆ÷ REACTOR 4800(ÏÃÃŰ²ÆÕÀû¹«Ë¾)£»ÐýÎлìºÏÒÇ HQ-601 (±±·½Í¬ÕýÉúÎï¼¼Êõ·¢Õ¹¹«Ë¾)£»Î¢ÐÍÌ¨Ê½Õæ¿Õ±Ã GQL-802 (½­ËÕº£ÃÅÊÐ÷è÷ëÒ½ÓÃÒÇÆ÷³§)£»PCRÑ­»·ÒÇ P9600 (ÃÀ¹úP¹«Ë¾)£»µçÓ¾²Û S-60 (ÉϺ£Ò½ÓÃÒÇÆ÷³§)£»Äý½ºÍ¼Ïñ´¦Àíϵͳ GIS (ÖйúÌìÄÜÓÐÏÞ¹«Ë¾)£»×ÏÍâÏß·Ö¹â¶È¼Æ T102 (ÉϺ£Ò½ÓÃÒÇÆ÷³§)£»È«×Ô¶¯Ê¯À¯°üÂñ»ú £¨ËÕÖÝÉúÎ﹤³Ì¹«Ë¾£©¡¢Á¬ÐøÇÐÆ¬»ú£¨ÉϺ£Ò½ÓÃÆ÷е³§£©¡£
Éè¼Æ¡¢ÊµÊ©¡¢ÆÀ¹ÀÕߣºµÚÒ»¡¢¶þ×÷ÕßÍê³É¡£
·½·¨£º
mRNA ÌáÈ¡£º¢Ù°´ÕÕTRIZOL·¨½øÐÐÌáÈ¡¡£ÔȽ¬´¦Àí²¡ÀíÐÔñ£ºÛºÍÕý³£Æ¤·ô£ºÈ¡×éÖ¯100 mg¼ÓÈë1 mL TRNzol£¬ÓÃÔȽ¬Æ÷½øÐÐÔȽ¬´¦Àí£¬ÒòΪ×éÖ¯½ÏÓ²ËùÒÔÁ¦¶ÈºÍʱ¼ä¼ÓÇ¿£¬ÑùÆ·µÄÌå»ýÒ»°ã²»³¬¹ýTRNzolÌå»ýµÄ10%¡£¢Ú½«ÔȽ¬ÑùÆ·ÔÚ15~30 ¡æ ·ÅÖÃ5 min£¬Ê¹µÃºËËáµ°°×¸´ºÏÎïÍêÈ«·ÖÀë¡£¢Û 4 ¡æ 10 000 r/min ÀëÐÄ10 min£¬È¡ÉÏÇå¡£¢ÜÿʹÓÃ1 mLTRNzol¼Ó0.2 mLÂȷ£¬¸ÇºÃ¹Ü¸Ç£¬¾çÁÒÕñµ´15 s£¬ÊÒηÅÖÃ3 min¡£¢Ý 4 ¡æ 10 000 r/minÀëÐÄ10~15 min£¬ÑùÆ·»á·ÖΪ3²ã£º»ÆÉ«ÓлúÏ࣬Öмä²ãºÍÉϲãÎÞɫˮÏ࣬RNAÖ÷ÒªÔÚË®ÏàÖУ¬°ÑË®ÏàÔ¼600 ¦ÌL×ªÒÆµ½Ð¹ÜÖС£¢ÞÔڵõ½µÄË®ÏàÈÜÒºÖмÓÈëµÈÌå»ýÒì±û´¼£¬»ìÔÈ£¬ÊÒηÅÖÃ20~30 min¡£¢ß 4 ¡æ 10 000 r/minÀëÐÄ10 min£¬È¥ÉÏÇå¡£ÀëÐÄǰRNA³Áµí¾­³£ÊÇ¿´²»¼ûµÄ£¬ÀëÐĺóÔڹܲàºÍ¹Üµ×Ðγɽº×´³Áµí¡£¢à¼ÓÈë1 mLÌå»ý·ÖÊýΪ0.75µÄÒÒ´¼Ï´µÓ³Áµí£¬Ã¿Ê¹ÓÃ1 mL TRNzolÖÁÉÙÓà 1 mLÌå»ý·ÖÊýΪ0.75µÄÒÒ´¼¶Ô³Áµí½øÐÐÏ´µÓ¡£¢á 4 ¡æ 5 000 r/minÀëÐÄ3 min¡£µ¹³öÒºÌ壬עÒâ²»Òªµ¹³ö³Áµí£¬Ê£ÓàµÄÉÙÁ¿ÒºÌå¶ÌÔÝÀëÐÄ£¬È»ºóÓÃǹͷÎü³ö£¬×¢Òâ²»ÒªÎüÆú³Áµí¡£¢âÊÒηÅÖÃÁÀ¸É£¨²»ÒªÁÀµÃ¹ý¸É£¬RNAÍêÈ«¸ÉÔïºóºÜÄÑÈܽ⣬ÁÀ¸É2.0~3.0 min¼´¿É£©£¬¼ÓÈë50 ¦ÌLÎÞºËøˮ£¬·´¸´´µ´ò¡¢»ìÔȳä·ÖÈܽâRNA¡£
¶ÔÌáÈ¡µÄmRNA½øÐд¿¶È¼ì²â£ºÈ¡10 ¦ÌL RNA ÑùÆ·£¬15 g/LÇíÖ¬ÌÇÄý½ºÉÏÑù½øÐеçÓ¾(µçÓ¾60 V£¬30 min)£¬¼ì²éRNA µÄÍêÕûÐÔ¡£×ÏÍâ·Ö¹â¹â¶È·¨²â¶¨RNA ÑùÆ·µÄA260ºÍA280Öµ£¬È·¶¨ÑùÆ·´¿¶È¡£ÌáÈ¡µÄRNA ½øÐÐÇíÖ¬ÌÇÄý½ºµçÓ¾5S£¬18S£¬28S ÇåÎú¿É¼û£¬ÇÒ28S ±È18S ´øÁÁ¶È´óÁ½Èý±¶£¬´øÓë´øÖ®¼äÎÞÃ÷ÏÔÍÏβÏÖÏ󣬱íÃ÷RNAÎÞ½µ½â£¬ÎÞÃ÷ÏÔµÄDNAÎÛȾ£¬RNA ÑùÆ·A260£¬A280 µÄ±ÈÖµ¾ùÔÚ1.8~2.0£¬ËµÃ÷RNA δ±»µ°°×ÖÊ¡¢·ÓÎÛȾ¡£
·´×ªÂ¼(cDNA»ñÈ¡)£º¢ÙÑϸñ°´ÕÕ²Ù×÷˵Ã÷½øÐУ¬¶øÇÒËùÓÃÆ÷Ãó¾ùºÍ×ÜRNAÌáȡһÑù£¨DEPCË®½þÅÝ£¬¸ßѹ£¬ºæ¿¾£©¡£×Ü·´Ó¦Ìå»ý20 ¦ÌL¡£¢ÚÑùÆ·»ìºÏÎïÖÆ±¸£ºÑùÆ· 4 ¦ÌL +Ëæ»úÒýÎï1 ¦ÌL£¬×ÜÌå»ý5 ¦ÌL£¬·ÅÈë-70 ¡æ ±ùÏä5 min£¬È»ºó·Å-35 ¡æ ±ùÏä±£´æ¡£¢Û·´×ªÂ¼Ã¸»ìºÏÎïµÄÖÆ±¸£ºÎÞºËøˮ 6 ¦ÌL¡¢5¡Ábuffer 4 ¦ÌL¡¢MgCl2 (25 mmol/L)2.4 ¦ÌL¡¢DNTP(10 mmol/L) 1 ¦ÌL¡¢Ribonidoner inhibitor 0.6 ¦ÌL·´×ªÂ¼Ã¸(RT)1 ¦ÌL ×ܹ²15 ¦ÌL¡£ÒªÑϸñ²Ù×÷¼ÓҺҪ׼ȷºÍ¿ìËÙ¡£¢Ü½«ÉÏÊöµÄÁ½ÖÖ»ìºÏÎï»ìÔÈ¡£25 ¡æ 5 min£¬42 ¡æ 60 min£¬70 ¡æ 15 min¡£ÌáǰÔÚ½ðÊôÔ¡ÒÇÉÏÉ趨¡£
PCRÀ©Ôö£º¢ÙÒýÎï¡£Gs¦ÁÒýÎÉÏÓÎÒýÎï 5¡¯-TCT GTG GGA GGA TGA AG-3¡¯£¬ÏÂÓÎÒýÎï 5¡¯-CGG TTG GTC TGG TTG TC-3¡¯£¬Ô¤¼ÆÀ©ÔöƬ¶Î339 bp£»¦Â-action ÒýÎÉÏÓÎÒýÎï5¡¯-CCG CCC TAG GCA CCA GGG TG-3¡¯£¬ÏÂÓÎÒýÎï5¡¯-GGC TGG GGT GTT GAA GGT CTC AAA-3¡¯£¬Ô¤¼ÆÀ©ÔöƬ¶Î286 bp¡£¢Ú°´ÕÕÒýÎï˵Ã÷Êé²Ù×÷£ºÒýÎïÅäÖÆ³É10 g/L¡£ÔÚPCRÑ­»·ÒÇÉÏÉ趨ºÃPCR ·´Ó¦µÄ±äÐÔ¡¢ÍË»ðºÍÑÓÉìÌõ¼þ94 ¡æ 60 s£¬58 ¡æ 90 s ºÍ 72 ¡æ 120 s ¹²35 ¸öÑ­»·¡£¢Û½«·´×ªÂ¼À´µÄcDNA½øÐÐPCRÀ©Ôö·´Ó¦¡£·´Ó¦Ìå»ý50 ¦ÌL¡£·´Ó¦ÌåϵÈçÏ£º10¡Ábuffer 5 ¦ÌL¡¢MgCl2£¨25 mmol/L£©2.4 ¦ÌL¡¢DNTP £¨2.5 mmol/L£©1 ¦ÌL¡¢ÉÏÓÎÒýÎï 0.5 ¦ÌL¡¢ÏÂÓÎÒýÎï 0.5 ¦ÌL¡¢CDNA²úÎï5 ¦ÌL¡¢ÎÞºËøˮ 29.5 ¦ÌL taqø 0.5 ¦ÌL¡£×ܹ² 50 ¦ÌL¡£ÓÃǹͷ·´¸´»ìÔÈ¡£·ÅÈëPCRÀ©ÔöÒÇÖУ¬É趨 PCR·´Ó¦µÄ±äÐÔ¡¢ÍË»ðºÍÑÓÉìÌõ¼þ·Ö±ðΪ 94 ¡æ 60 s¡¢58 ¡æ 90 s ºÍ72 ¡æ 120 s ¹²35¸öÑ­»·¡£
À©Ôö²úÎïµçÓ¾Óë·ÖÎö£º¢Ù²úÎïµçÓ¾ÖÆ±¸£ºµçÓ¾»º³åÒº:5¡ÁTBE£¬ÔÙ½«5¡ÁTBEÏ¡ÊÍ10±¶³É0.5TBE(¹¤×÷ҺŨ¶È)¡£0.6 gÇíÖ¬ÌÇ+40 mLµçÓ¾»º³åÒº£¬Î¢²¨Â¯Öлð30 sÖÁ·ÐÌÚÈÛ»¯µÄÇíÖ¬ÎïÀäÈ´ÖÁ60 ¡æ ʱ¼ÓÈë10 g/Lä廯ÒÒ¶§4 ¦ÌL£¬³ä·Ö»ìÔÈ£¬½«ÎÂÈȵÄÄý½ºµ¹ÈëÒÑÖúÃÊá×ӵĽºÄ¤ÖУ¬ÔÚÊÒÎÂÏ·ÅÖÃ30~45 minºó½øÐеçÓ¾¡£¢Ú½«Êá×ÓСÐİγö£¬maker 8 ¦ÌLºÍÑùÆ··Ö±ð¼Óµ½¿×ÖС£½«Äý½ºÖÃÈëµçÓ¾²ÛÖУ¬½øÐеçÓ¾¡£µçѹ80~100 mV£¬20~30 min¡£ÔÚ×ÏÍâÏß·Ö¹â¼ÆÏ¹۲죬ÈçÓÐÄ¿±êÌõ´ø³öÏÖ¡£½«Äý½ºÖÃÈëÄý½ºÍ¼Ïñ·ÖÎöϵͳ£¬½øÐзÖÎö¡£¼Ç¼Ŀ±êÌõ´øºÍÄڲεĻҶȱÈÖµ¡£¢Û²¡ÀíÐÔñ£ºÛºÍÕý³£Æ¤·ôµÄËÕľ¾«-ÒÁºìȾɫºÍÃâÒß×éÖ¯»¯Ñ§£¨SP·¨£©È¾É«¡£
ËÕľ¾«-ÒÁºìȾɫ£ºÈ¡ÖƱ¸ºÃµÄ±ê±¾ÒÔ¿àζËá¹Ì¶¨24 hÒÔÉÏ¡£ÓÃÌå»ý·ÖÊýΪ0.5µÄÒÒ´¼·´¸´Æ¯Ï´Ö±µ½ÎÞ»ÆÉ«³öÏÖ£¬ÒÒ´¼ÍÑË®¹²2 h£¬¶þ¼×±½Í¸Ã÷30 min£¬½þÀ¯3 h£¬°üÂñ¡£Ê¯À¯Á¬ÐøÇÐÆ¬¡£ÀÌÆ¬¿ÉÓ󣹿²£Æ¬¡£60 ¡æ ÎÂÏäÖп¾Æ¬30 min¡£ÍÑÀ¯30 min£¬Ìå»ý·ÖÊýΪ0.95µÄÒÒ´¼¹ýÁ½´Î£¬Ìå»ý·ÖÊýΪ0.8µÄÒÒ´¼¹ýÒ»´Î¡£Mayer¡¯s ËÕľ¾«È¾É«5~ 10 min£¬Á÷Ë®³åÏ´ 10 min£¬ÒÁºìȾɫƬ¿Ì¡£Ìå»ý·ÖÊýΪ0.95µÄÒÒ´¼¹ýÁ½´Î£¬Ìå»ý·ÖÊýΪ1µÄÒÒ´¼¹ýÒ»´Î£¬Ê¯Ì¼Ëá- ¶þ¼×±½ÖнþÅÝ1.0~2.0 min£¬¶þ¼×±½¹ýÁ½´Î£¬²»Ðèºæ¸É£¬¼´¿ÉÓÃÖÐÐÔÊ÷½º·â¹Ì¡£ÖÃÓڹ⾵Ϲ۲첡ÀíÐÔñ£ºÛºÍÕý³£Æ¤·ôµÄ½á¹¹²¢ÅÄÕÕ¡£
ÃâÒß×éÖ¯»¯Ñ§È¾É«£ºÈ¡ÖƱ¸ºÃµÄ±ê±¾ÒÔ¿àζËá¹Ì¶¨24 hÒÔÉÏ¡£ÓÃÌå»ý·ÖÊýΪ0.5µÄÒÒ´¼·´¸´Æ¯Ï´Ö±µ½ÎÞ»ÆÉ«³öÏÖ£¬ÒÒ´¼ÍÑË®¹²2 h£¬¶þ¼×±½Í¸Ã÷30 min,½þÀ¯3 h£¬°üÂñ¡£Ê¯À¯Á¬ÐøÇÐÆ¬¡£×÷ÃâÒß×黯ÐèÓù軯²£Æ¬¡£½«Ê¯À¯ÇÐÆ¬³£¹æÍÑÀ¯£¬Ìå»ý·ÖÊýΪ0.03µÄH2O2-¼×´¼ÊÒÎÂÏ·õÓý10 min£¬ÒÔ×è¶ÏÄÚÔ´ÐÔ¹ýÑõ»¯Îïø£¬ÕôÁóË®³åÏ´£¬PBS½þÅÝ5 min£¬µÎ¼ÓÕý³£É½ÑòѪÇ幤×÷Òº·â±Õ£¬ÊÒηõÓý 30 min£¬Ë¦È¥¶àÓàÒºÌ壬·ÅÈë¸ßѹ¹øÄÚ½øÐÐÈÈÐÞ¸´,ʹ¿¹Ô­³ä·Ö±©Â¶¡£15 minºóÈ¡³ö¡£¼ÓÈë1¡Ã100Ï¡Ê͵ÄÒ»¿¹£¨Íÿ¹ÈË£©£¬30 min¡£PBS³åÏ´£¬µÎ¼ÓÉúÎïËØ±ê¼Ç¶þ¿¹¹¤×÷Òº£¨¿¹Íã©£¬37 ¡æ ·õÓý20 min£¬PBS³åÏ´3´Î£¬ÓÃDABÏÔÉ«£¬ËÕľ¾«¸´È¾£¬³£¹æÍÑË®¡¢·â¹Ì£¬ÏÔ΢¾µÏ¹۲졣ϸ°ûĤ°û½¬²àȾ³É»ÆÉ«ÎªÑôÐÔ¡£Åжϱê×¼£ºËùÓÐϸ°û¾ùÎÞ»ÆÈ¾ÎªÒõÐÔ£»²¿·Öϸ°û»ÆÈ¾ÎªÈõÑôÐÔ£»È«²¿Ï¸°û»ÆÈ¾ÎªÑôÐÔ£»È«²¿Ï¸°û»ÆÈ¾ÇÒÑÕÉ«¼ÓÉî³Ê»ÆºÖÉ«»òºÖɫΪǿÑôÐÔ¡£½áºÏµ°°×±í´ïÌØÐÔ½øÐмø¶¨¡£
Ö÷Òª¹Û²ìÖ¸±ê£º¢Ù´Ì¼¤ÐÔGµ°°×ÔÚ²¡ÀíÐÔñ£ºÛÖеĻùÒò±í´ï£º¼Ç¼Ŀ±êÌõ´øºÍÄڲεĻҶȱÈÖµ¡£¢Ú²¡ÀíÐÔñ£ºÛºÍÕý³£Æ¤·ôµÄËÕľ¾«-ÒÁºìȾɫºÍÃâÒß×éÖ¯»¯Ñ§È¾É«ÏÔʾµÄ´Ì¼¤ÐÔGµ°°×±í´ïÇé¿ö¡£
ͳ¼ÆÑ§·½·¨£ºÓɵÚÒ»×÷ÕßÓÃSSPSͳ¼ÆÈí¼þ½øÐÐt¼ìÑ飬P < 0.05Ϊ²îÒìÓÐÏÔÖøÐÔÒâÒ壬P < 0.01Ϊ²îÒìÓзdz£ÏÔÖøÐÔÒâÒå¡£

2 ½á¹û

2.1 ×ÜRNAÌáÈ¡ ÌáÈ¡µÄRNA½øÐÐÇíÖ¬ÌÇÄý½ºµçÓ¾ 5S£¬18S£¬28S ÇåÎú¿É¼û£¬ÇÒ28S±È18S´øÁÁ¶È´óÁ½Èý±¶£¬´øÓë´øÖ®¼äÎÞÃ÷ÏÔÍÏβÏÖÏ󣬱íÃ÷RNA ÎÞ½µ½â£¬ÎÞÃ÷ÏÔµÄDNAÎÛȾ£»RNAÑùÆ·A 260/A 280µÄ±ÈÖµ¾ùÔÚ1.8~2.0£¬ËµÃ÷RNAδ±»µ°°×ÖÊ¡¢·ÓÎÛȾ¡£
2.2 PCRÀ©Ôö²úÎïµçÓ¾½á¹û Ä¿±êÌõ´øºÍÄÚ²ÎÌõ´øÇåÎú£¬ÎÞÃ÷ÏÔÍÏβÏÖÏ󡣺ÍMAKER¶ÔÕÕ£¬Ä¿±êÌõ´øºÍÄÚ²ÎÌõ´øµÄÏà¶Ô·Ö×ÓÖÊÁ¿·ûºÏÒªÇó£¬ÎªÊµÑéËùÐèÌõ´ø(ͼ1£¬2)¡£

 

·Ö±ð¼Ç¼¸÷Ìõ´øµÄ»Ò¶ÈÖµ£¬²¢¼Ç¼Ŀ±êÌõ´øºÍÄÚ²ÎÌõ´ø»Ò¶ÈÖµ±ÈÖµ£¬²¡ÀíÐÔñ£ºÛ×éΪ0.73¡À0.04£¬Õý³£Æ¤·ô×éΪ0.49¡À0.03£¬Á½×é±È½Ï²îÒìÓÐÏÔÖøÐÔÒâÒ壨P < 0.05£©¡£
2.3 ËÕľ¾«-ÒÁºìȾɫ½á¹û ÓëÕý³£Æ¤·ô±È½Ï£¬²¡ÀíÐÔñ£ºÛ±íƤ½Ç»¯ÑÏÖØ£¬½Ïºñ¡¢ÎÞÆ¤Ö¬ÏÙ¡¢º¹ÏÙ¡¢Ã«ÄÒ¡£ÕæÆ¤²ã½Ïºñ£¬º¬ÓдóÁ¿µÄ½ºÔ­ÏËά£¬ÅÅÁÐÎÉÂÒ£¬º¬Óн϶à³ÉÏËάϸ°û£¬¼°Ã«Ï¸Ñª¹Ü¡£ËùÈ¡±ê±¾·ûºÏʵÑéÐèÒª(ͼ3)¡£

 

 

2.4 ´Ì¼¤ÐÔGµ°°×µÄ±í´ï ¼ûͼ4¡£

 

´ÓÃâÒß×éÖ¯»¯Ñ§È¾É«À´¿´£¬²¡ÀíÐÔñ£ºÛºÍÕý³£Æ¤·ô¾ùÓÐϸ°û°û½¬²à»ÆºÖɫϸ°û´æÔÚ£¬¾ù·Ö²¼ÔÚ±íÆ¤µÄ»ùµ×ϸ°ûÄÚ¡¢ÕæÆ¤µÄ³ÉÏËάϸ°ûÄÚºÍëϸѪ¹ÜµÄÄÚÆ¤Ï¸°ûÄÚ£¬Á½ÕßÎÞ²îÒì¡£¸ù¾Ý»ÆÈ¾µÄÉîdzÆÀ¹À£º²¡ÀíÐÔñ£ºÛºÍÕý³£Æ¤·ôµÄ´Ì¼¤ÐÔGµ°°×ÔÚ±íÆ¤µÄ»ùµ×ϸ°ûÄÚ±í´ïÇé¿öÏàËÆ£¬ÎÞÃ÷ÏÔ²îÒì¡£ÕæÆ¤µÄ³ÉÏËάϸ°ûÄÚºÍëϸѪ¹ÜµÄÄÚÆ¤Ï¸°ûÄÚ²¡ÀíÐÔñ£ºÛµÄ±í´ïÇ¿ÓÚÕý³£Æ¤·ô¡£

3 ÌÖÂÛ

Gµ°°×ÊÇÄÜÓëÄñàÑßʺËÜÕËá½áºÏ£¬¾ßÓÐË®½âGTPÉú³ÉGDP¼´¾ßÓÐGTP ø»îÐԵĵ°°×£¬Î»ÓÚϸ°ûĤ°û½¬ÃæµÄÍâÖܵ°°×£¬Ò»°ãÊÇÖ¸ÓëĤÊÜÌåżÁªµÄÒìÔ´Èý¾ÛÌå[5]£¬ÓÉÈý¸öÑÇ»ù×é³ÉËüÃÇÊǦÁÑÇ»ù¡¢¦ÂÑÇ»ù¡¢¦ÃÑÇ»ù£¬ÖÁÉÙÓÐ21ÖÖ²»Í¬µÄ¦ÁÑÇ»ù£¬5ÖÖ¦ÂÑÇ»ùºÍ8ÖÖ¦ÃÑÇ»ù[6]¡£Gµ°°×·ÖÀàÓÐÐí¶àÖÖ£¬³£¸ù¾ÝÆä¶ÔÏÙÜÕËá»·»¯Ã¸£¨AC£©µÄ×÷Ó㬿ɷÖΪ¼¤¶¯ÐÍGµ°°×£¨Gs£©£¬ÒÖÖÆÐÍGµ°°×£¨Gi£©ºÍÁ×֬øCÐÍGµ°°×£¨Gp£©¡£ÓÉÓÚGs ºÍGi ·Ö±ð¾ßÓд̼¤ºÍÒÖÖÆÏÙÜÕËá»·»¯Ã¸µÄ×÷Óã¬Òò´ËÏÙÜÕËá»·»¯Ã¸µÄ»îÐÔÓëÁ½ÖÖGµ°°×µÄ±í´ïˮƽÓйØ,ÔÚÐí¶àϸ°ûϵÖоù·¢ÏÖGµ°°×µÄº¬Á¿ÓëÏÙÜÕËá»·»¯Ã¸/cAMPÐźÅϵͳµÄ¼¤»îÖ±½ÓÏà¹Ø[7]¡£ÓÉÓڴ̼¤ÐÔGµ°°×·ÖÀà±È½Ïµ¥Ò»£¬¶øÇÒÆä×÷ÓÃÔںܶ༲²¡ÖеÄÑо¿ÖÐÒѾ­µÃµ½ÑéÖ¤£¬ËùÒÔ±¾ÊµÑéÒÔ²¡ÀíÐÔñ£ºÛºÍÕý³£Æ¤·ôÖд̼¤ÐÔGµ°°×µÄ±í´ïΪÑо¿¶ÔÏó¡£
Gµ°°×żÁªµÄÐźŴ«µ¼ÏµÍ³ÓÉGµ°°×żÁªÊÜÌå(GPRS)£¬Gµ°°×ºÍЧӦÆ÷ (ÏÙÜÕËá»·»¯Ã¸¡¢Á×֬øC¡¢CaÀë×ÓͨµÀ¡¢KÀë×ÓͨµÀµÈ) ×é³É¡£GPRSÊÇÒÑÖª3ÀàÉæ¼°¿çĤÐźŴ«µ¼µÄĤÊÜÌåÖ®Ò»¡£Ä¿Ç°ÒÑÓÐ2 000¶àÖÖGPRSµÃµ½È·ÈÏ[8]¡£Õâ¹¹³ÉÁËÈËÌå×î´óµÄµ°°×Öʳ¬¼Ò×å¡£Gµ°°×´«µ¼ÓÉGPRS½ÓÊܵÄÐźţ¬ÔÙÒÔGµ°°×½âÀëÑÇ»ù×÷Ϊ´«µ¼Î»î»¯ÏàӦøºÍÀë×ÓͨµÀ£¬²úÉúÖØÒªµÄµÚ¶þÐÅʹ´Ó¶øÒýÆð°ûÄÚÏàÓ¦µÄÉúÎï·´Ó¦¡£GPRSÊÇÒ»ÀàÖØÒªµÄϸ°û±íÃæÊÜÌ壬¿ç¹ýϸ°ûË«Á×Ö¬²ã£¬²¢ÄÜ´«µ¼¸÷ÖÖϸ°ûÍâµÄµ°°×Öʳ¬¼Ò×å[9-11]¡£
Ò»°ãÈÏΪ£¬ÔÚÐźÅתµ¼¹ý³ÌÖÐGµ°°×Ö÷ÒªÆðµ½ÒÔÏÂ×÷ÓÃ[12-13]£º¢ÙÐźŷŴó×÷ÓãºÍ¨³£Çé¿öÏ£¬Ò»¸öϸ°ûÍâÐźż¤»îµÄÊÜÌå¿ÉÒÔ¼¤»îÐí¶àGµ°°×£¬´Ó¶øÏòϸ°ûÄÚ´«µÝ¸ü¶àµÄÐźţ¬Æðµ½¼¶Áª×÷Óã»ÁíÍ⣬ÔÚһЩÇé¿öÏ£¬Ï¸°ûÍâÐźÅÓëÊÜÌå½áºÏµÄʱ¼ä±È½Ï¶Ì£¬²»ÄܲúÉú×ã¹»µÄ·Å´ó×÷Ó㬵«ÊÇÓëÖ®Ïà±È£¬Gµ°°×½áºÏGTP¶ø±»¼¤»îµÄʱ¼ä³¤Ò»Ð©£¬ÓÐ10~15 s£¬ËùÒÔËäÈ»ÊÜÌåÓëÍâ½çÐźÅÒѾ­·ÖÀ룬µ«ÊÇGµ°°×ÈÔÔÚ¼¤»îÏà¹ØÃ¸ÏµÍ³£¬Ô´Ô´²»¶ÏµØÏòϸ°ûÄÚ´«µÝÐźš£¢Ú·Ö×Ó¿ª¹Ø×÷ÓãºÐźÅתµ¼¹ý³ÌÖУ¬Gµ°°×ÌṩÁËÒ»¸öÖØÒªµÄµ÷½Ú¿ØÖÆ×÷Óã¬ËüÓëGTPµÄ½áºÏ¿ªÆôÁËÐźÅת»»Í¨Â·¡£ÁíÍ⣬Gµ°°××ÔÉí¹²¼ÛÐÞÊμ°Å¨¶ÈµÄ¸Ä±äÒ²¶¼»áÓ°ÏìÊÜÌåºÍø֮¼äżÁªµÄÓÐЧÐÔ£¬Ï¸¾ú¶¾ËØÐ§Ó¦ÄܺܺõØËµÃ÷¸Ã¹Ûµã¡£Õý³£µÄÉúÀíÌõ¼þÏ£¬Gµ°°×ÓëGTP¡¢GDP½áºÏ״̬µÄ¿ÉÄæ±ä»¯Ê¹Ò»Ð©ÐźÅתµ¼¾«È·¶øÊʶȡ¢²»ÊdzÖÐøµÄ¶øÊǶÔϸ°ûÍâÐźŵÄ˲¼äµÄ·´Ó¦£¬Ò»µ©ÆÆ»µÁËÕâÖÖÕý³£µÄÕý¡¢¸º·´À¡»úÖÆ£¬Ï¸°û¾Í»á·¢Éú²¡±ä¡£ËäÈ»£¬Gµ°°×ÔÚÐźÅתµ¼¹ý³ÌÖоßÓÐÐźŷŴóµÄ×÷Ó㬵«ÊÇ£¬ÕâÖÖ·Å´ó×÷Óò»ÄÜÎÞÏ޵ش󣬱ØÐëÊܵ½ÊʶȵĿØÖÆ£¬Õâ¾ÍÌåÏÖÁËGµ°°×µÄ·Ö×Ó¿ª¹Ø×÷ÓÃ[14]¡£ÁíÍâGµ°°×Ò²¿ÉÓÕµ¼Ï¸°ûµòÍö[15]¡£
Ðí¶àÑо¿Ö¤ÊµÉË¿ÚÒºÖÐbFGF¡¢TGF-¦ÂºÍPDGF µÈ¶àëÄÉú³¤Òò×ӵĺ¬Á¿Ã÷ÏÔÉý¸ß£¬ÕâÖÖ¸ßŨ¶ÈµÄÉú³¤Òò×ÓÔÚñ£ºÛÔöÉúʱ³ÖÐø´æÔÚ£¬¶øñ£ºÛ³ÉÊìºóÔò»Ö¸´Õý³£Ë®Æ½[16]¡£½üÄêµÄÑо¿±íÃ÷£¬Éú³¤Òò×ÓÐźÅÖ÷Ҫͨ¹ýRas -ͨµÀ´«µÝ,»¹Éæ¼°Ca2+¡¢IP3¡¢DG - PKC ͨµÀ£¬¶øÕâЩͨµÀÒ²´æÔÚÓÚGµ°°×żÁªµÄÐźŴ«µ¼ÏµÍ³ÖУ¬Ö÷Òª³É·ÖÒ²ÊÇGµ°°×żÁªµÄÐźŴ«µ¼ÏµÍ³ÖÐÖØÒªµÄЧӦÆ÷£¬ÖÁÓÚÊÇÓÉGs»¹ÊÇÆäËûµÄGµ°°×½éµ¼ÐèÒª½øÒ»²½µÄÑо¿¡£GsÒѾ­Ö¤Êµ¿ÉÒÔ¼¤»îCa2+ͨµÀ£¬¿çĤÐźÅתµ¼ÊÇÒ»¸öºÜ¸´ÔÓµÄϵͳ£¬¶àÌõÐźŴ«µ¼Í¾¾¶²¢´æºÍ´æÔÚ½»²æ£¬¶àÌõÐźŴ«µ¼Í¾¾¶¿ÉÄÜͨ¹ýͬһЧӦÆ÷Æð×÷Óã¬Ò²¿ÉÄÜÒ»ÌõÐźŴ«µ¼Í¾¾¶Í¨¹ý¶à¸öЧӦÆ÷Æð×÷Óá£Éú³¤Òò×ӿɻRasͨµÀ£¬»¹»î»¯ÈÈÐݿ˵°°×25/27²¢Ó°Ï켡¶¯µ°°×ÐγɺͷÖÃÚ£¬ºóÕßÓëñ£ºÛÂÎËõÓйء£½á¹ûÏÔʾñ£ºÛÔöÉúÔ½Ã÷ÏÔPKC»îÐÔÉý¸ßÔ½ÏÔÖø,½Òʾ²¡ÀíÐÔñ£ºÛ×éÖ¯ÖÐPKC»î»¯È±·¦¶Ôϸ°ûÉú³¤µÄ¸º·´À¡ÒÖÖÆ¡£FasR-FasÔÚµ÷¿ØÏ¸°ûÔöÖ³ºÍµòÍöÖÐËùÆðµÄÖØÒª×÷ÓÃÔÚÖÚ¶àÑо¿ÁìÓòÖÐÒѵõ½¹ã·ºµÄÖØÊÓ¡£¶øÇÒFas½éµ¼µÄµòÍö»¹±»ÈÏΪÊdzÉÏËάϸ°ûÄÚËÀÍöÐźŴ«µÝµÄ×îÖ÷ҪͨµÀ[17]¡£Õâ±íÃ÷ñ£ºÛ¸í´ñÕâÖÖFas½éµ¼µÄµòÍö¿¹ÐÔÊǵ¼ÖÂñ£ºÛ¸í´ñ³ÉÏËάϸ°ûÒì³£ÔöÖ³(¸ßÔöÖ³ µÍµòÍö)µÄϸ°ûÉúÎïѧ»úÖÆÖ®Ò»[18]¡£Gµ°°×Ò²²ÎÓëÁ˶àÖÖϸ°ûµÄµòÍö¹ý³Ì£¬È»¶øËüÊÇͨ¹ýFas½éµ¼µÄµòÍö£¬»¹ÊÇÁíÓÐͨµÀÕ⻹Ðè½øÒ»²½µÄÑо¿¡£µ«ÊÇPKC×÷ΪGµ°°×żÁªµÄÐźŴ«µ¼ÏµÍ³ÖÐÖØÒªµÄЧӦÆ÷£¬ÔÚϸ°ûµÄÐźŴ«µ¼ÖÐÆð×ŷdz£ÖØÒªµÄ×÷Óᣱ¾ÊµÑ鲡ÀíÐÔñ£ºÛµÄÕæÆ¤³ÉÏËάϸ°ûºÍѪ¹ÜÄÚÆ¤Ï¸°û´Ì¼¤ÐÔGµ°°×±í´ïÃ÷ÏÔ¸ßÓÚÕý³£Æ¤·ô£¬ÊÇ·ñ´Ì¼¤ÐÔGµ°°×ÓëPKCÏàżÁª£¬ÓÉÓÚǰÕߵĸ߱í´ïÒýÆðPKC »îÐÔÉý¸ß£¬´Ó¶øÈ±·¦¶Ôϸ°ûÉú³¤µÄ¸º·´À¡ÒÖÖÆ£¬ÒýÆð³ÉÏËάϸ°ûµÄ¹ý¶ÈÔöÖ³£¬´Ù½ø²¡ÀíÐÔñ£ºÛµÄÐγɡ£»¹Ðè½øÒ»²½µÄÑо¿¡£
´Ó±¾ÊµÑéµÄ½á¹ûÀ´·ÖÎö£¬²¡ÀíÐÔñ£ºÛºÍÕý³£Æ¤·ôÖд̼¤ÐÔGµ°°×Ö÷Òª±í´ïÔÚÕæÆ¤µÄ³ÉÏËάϸ°ûÄÚ¡£²¡ÀíÐÔñ£ºÛµÄÕæÆ¤³ÉÏËάϸ°û´Ì¼¤ÐÔGµ°°×±í´ïÃ÷ÏÔ¸ßÓÚÕý³£Æ¤·ô£¬¶øÇҴ̼¤ÐÔGµ°°×Ôںܶàϸ°ûϵÖж¼Æðµ½´Ù½øÏ¸°ûÔöÖ³µÄ×÷ÓᣴӶøÈÏΪ£¬Õâ¿ÉÄÜÓë³ÉÏËάϸ°ûÔöÖ³Óйء£¶ÔÓÚʲôԭÒòÒýÆð´Ì¼¤ÐÔGµ°°×µÄ¸ß±í´ï£¬Æä¾ßÌå»úÖÆÉÐÓдýÓÚ½øÒ»²½µÄÑо¿¡£
±¾ÊµÑéµÄÃâÒß×黯½á¹ûÏÔʾ²¡ÀíÐÔñ£ºÛºÍÕý³£Æ¤·ôÖд̼¤ÐÔGµ°°×ÔÚëϸѪ¹ÜÄÚÆ¤Ï¸°ûÄÚ´æÔÚÏÔÖø²îÒìµÄ±í´ï£¬²¡ÀíÐÔñ£ºÛµÄ±í´ïÃ÷ÏÔ¸ßÓÚÕý³£Æ¤·ôµÄ±í´ï£¬±íÃ÷´Ì¼¤ÐÔGµ°°×¿ÉÄܲÎÓëÔöÉúÐÔñ£ºÛÖÐѪ¹ÜÄÚÆ¤Ï¸°ûµÄÔöÖ³£¬¶øÇҴ̼¤ÐÔGµ°°×¿ÉÄܶÔѪ¹ÜÄÚÆ¤Ï¸°ûµÄÔöÖ³´æÔÚ´Ù½ø×÷Óᣵ«ÊÇÆä¾ßÌå»úÖÆ»¹ÓдýÓÚ½øÒ»²½Ñо¿¡£
×ܶøÑÔÖ®£¬²¡ÀíÐÔñ£ºÛºÍÕý³£Æ¤·ô¾ùÓд̼¤ÐÔGµ°°×µÄ±í´ï£»Æä±í´ïÔÚ±íÆ¤µÄ»ùµ×ϸ°ûÄÚÎÞÃ÷ÏÔ²îÒ죻µ«ÔÚÕæÆ¤µÄ³ÉÏËάϸ°ûÄÚºÍëϸѪ¹ÜÄÚÆ¤Ï¸°ûÄڵıí´ï´æÔÚÃ÷ÏÔ²îÒ졣ǰÕ߸ßÓÚºóÕß¡£Õâ¿ÉÄÜÓ벡ÀíÐÔñ£ºÛÖгÉÏËάϸ°ûºÍëϸѪ¹ÜÄÚÆ¤Ï¸°ûµÄÔöÖ³Óйء£

4 ²Î¿¼ÎÄÏ×

1 Wang ZX,Li SR,Wu J.Zhongguo Meirong Zhengxing Waike Zazhi 2007;18(1):77-79
ÍõÕäÏé,ÀîÊÀÈÙ,Îâ¾ü. Ô­°©»ùÒòN33ÔÚÔöÉúÐÔñ£ºÛÖбí´ïµÄÑо¿[J]. ÖйúÃÀÈÝÕûÐÎÍâ¿ÆÔÓÖ¾,2007,18(1):77-79
2 Cheng Y,Long JH.Zhonghua Shaoshang Zazhi 2004;20(6):368
³ÌÓÂ, Áú½£ºç. ºÚÆ¤ËØ1ÊÜÌåÔÚÈËÌåÕý³£Æ¤·ôºÍÔöÉúÐÔñ£ºÛÖеıí´ïÓë·Ö²¼[J]. ÖлªÉÕÉËÔÓÖ¾, 2004, 20(6):368
3 Materazzi S, Pellerito S, Di Serio C,et al. Analysis of protease-activated receptor-1 and -2 in human scar formation. J Pathol 2007;212(4): 440-449
4 Liu HW, Cheng B, Yu WL,et al. Angiotensin II regulates phosphoinositide 3 kinase/Akt cascade via a negative crosstalk between AT1 and AT2 receptors in skin fibroblasts of human hypertrophic scars.Life Sci 2006;79(5):475-483
5 Chen JL, Ge-zhi WENG,Ni HX.Shengwu Gongcheng Xuebao 2001;17(2):113-117
³Â¾ÞÁ«,Ge-zhi WENG, ÄߺºÏé. Gµ°°×¼°ÆäżÁªÐźŴ«µ¼Í¾¾¶µÄÑо¿½øÕ¹[J].ÉúÎ﹤³Ìѧ±¨, 2001,17(2):113-117
6 Alfredoulloa AP,Michael Conn.G-protein coupled receptors and the G-protein family. handbook of physiology ,section 7,chapter 6.Eds by :H Maurice Goodman. New York ,Oxford University press 1997
7 Chin KV,Yang WL,Ravatn R,et al. Reinventing the wheel of cyclic AMP novel mechanisms of cAMP signaling. Ann N Y Acad Sci 2002;968:49-64
8 Steneberg P, Rubins N, Bartoov-Shifman R, et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 2005;1(4):245-258
9 Guo YZ,Zhang HY,Liang L.Shengming De Huaxue 2004; 24(5):412-414
¹ùÖ¾ÔÆ,ÕÅ»³Óå,ÁºÁú. Gµ°°×żÁªÊÜÌåµÄ½á¹¹Ó빦ÄÜ[J]. ÉúÃüµÄ»¯Ñ§, 2004, 24(5):412-414
10 Wang B,Sun RB.Guowai Yixue:Yaoxue Fence 2005;32(1):49-52
Íõ²ª£¬ËïÈð±ó. Ò©Îï×÷ÓúÍÖÎÁÆÐ½øÕ¹:Gµ°°×żÁªÊÜÌå¼°ÐźÅתµ¼Ïà¹ØÐ¸ÅÄî[J].¹úÍâҽѧ:ҩѧ·Ö²á, 2005,32(1):49-52
11 Schnell S, Schaefer M, Schofl C. Free fatty acids increase cytosolic free Calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Mol Cell Endocrinol 2007;263(1-2):173-180
12 Takigami S, Mori Y, Tanioka Y, et al. Morphological evidence for two types of mammalian vomeronasal system. Chem Senses 2004;29(4): 301-310
13 Couvillon AD, Exton JH. Role of heterotrimeric G-proteins in lysophosphatidic acid-mediated neurite retraction by RhoA-dependent and independent mechanisms in N1E-115 cells. Cell Signal 2006; 18(5):715-729
14 Mao WP,Xu F.Huanjing Yu Zhiye Yixue 2004;22(2): 34-36
ëΰƽ,Ðí·æ. ϸ°ûµòÍö¹ý³ÌÖеÄÐźÅתµ¼[J].»·¾³Óëְҵҽѧ, 2004,22(2):34-36
15 Feng F.Guowai Yixue:Weishengxue Fence 2000;27(4)£º235-238
·ë·á.½ðÊôÔªËØÓëϸ°ûµòÍö[J].¹úÍâҽѧ:ÎÀÉúѧ·Ö²á,2000, 27(4):235-238
16 Maizels ET,Kline M,Kline M.Heat-shock protein-25/27 phosphorylation by the delta isoform of protein kinase C. Biochem J 1998;332(Pt 3): 703-712
17 Li XJ,Gao JH,Lu F.Diyi Juyi Daxue Xuebao 2000;24(3):231-232
ÀèС¼ä,¸ß½¨»ª,³·å. ²¡ÀíÐÔñ£ºÛ³ÉÏËάϸ°ûFasÊÜÌå¼°Bc1-2µ°°×µÄ±í´ï[J].µÚÒ»¾üÒ½´óѧѧ±¨, 2000,24(3):231-232
18 Noguchi K, Shitashige M, Endo H, et al. Binary regulation of interleukin (IL)-6 production by EP1 and EP2/EP4 subtypes of PGE2 receptors in IL-1beta-stimulated human gingival fibroblasts. J Periodontal Res 2002;37(1):29-36

 


¡¶Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´¡·ÔÓÖ¾Éç
µØÖ·£ºÉòÑô1200ÓÊÕþÐÅÏä Óʱࣺ110004 ´«Õ棺+86 24 23394178